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Uromodulin (Tamm–Horsfall protein) is the most abundant
protein excreted in the urine under physiological conditions.
It is exclusively produced in the kidney and secreted into the
urine via proteolytic cleavage. Its biological function is still
not fully understood. Uromodulin has been linked to
water/electrolyte balance and to kidney innate immunity.
Also, studies in knockout mice demonstrated that it has a
protective role against urinary tract infections and renal
stone formation. Mutations in the gene encoding uromodulin
lead to rare autosomal dominant diseases, collectively
referred to as uromodulin-associated kidney diseases. They
are characterized by progressive tubulointerstitial damage,
impaired urinary concentrating ability, hyperuricemia, renal
cysts, and progressive renal failure. Novel in vivo studies
point at intracellular accumulation of mutant uromodulin as a
key primary event in the disease pathogenesis. Recently,
genome-wide association studies identified uromodulin as a
risk factor for chronic kidney disease (CKD) and hypertension,
and suggested that the level of uromodulin in the urine could
represent a useful biomarker for the development of CKD. In
this review, we summarize these recent investigations,
ranging from invalidation studies in mouse to Mendelian
disorders and genome-wide associations, which led to a
rediscovery of uromodulin and boosted the scientific and
clinical interest for this long discovered molecule.
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BIOLOGY OF UROMODULIN
In the early fifties, Tamm and Horsfall1 described a
mucoprotein that could be purified from urine and inhibited
viral hemagglutination. The protein, referred to as Tamm–-
Horsfall protein, is the most abundant protein in urine
under physiological conditions.2 In 1985, Muchmore and
Decker3 isolated a protein from the urine of pregnant women
that they called uromodulin in relation with its immuno-
suppressive activity documented in vitro. Two years later,
Tamm–Horsfall protein and uromodulin were shown to be the
same protein in a seminal work by Pennica et al.4 The term
uromodulin will be used hereafter in this review.
Protein sequence and domain composition
Uromodulin is synthesized as a 640 amino-acid precursor.
The protein enters the secretory pathway where it is
glycosylphosphatidylinositol anchored, glycosylated, and
sorted to the apical plasma membrane of epithelial cells.
The rate-limiting step in uromodulin maturation is the
processing in the endoplasmic reticulum (ER), likely because
of the complex tertiary structure given by its high number of
cysteine residues (48; 7% of amino-acid content), all engaged
in the formation of intramolecular disulfide bonds.5 The
molecular weight of uromodulin (105 kDa) is significantly
contributed (30%) by N-glycosylation. Evidence for O-
glycosylation has also been reported.6 The presence of such
high glycan content is important for the chemico-physical
properties and function of uromodulin (see below). The
domain composition of uromodulin includes a leader
peptide directing its entry in the secretory pathway, three
epidermal growth factor (EGF)-like domains (EGF-II and
EGF-III predicted to be calcium binding), a central domain
of unknown function (named D8C as it contains eight
conserved cysteines), a zona pellucida (ZP) domain, and
a glycosylphosphatidylinositol-anchoring site (predicted at
position 614; Figure 1a). EGF-like domains are found in
many secreted and extracellular proteins, and are thought to
have a role in processes of adhesion, coagulation, and
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receptor–ligand interaction. In uromodulin, these modules
are likely important for protein–protein interaction. The ZP
domain is found in a variety of extracellular eukaryotic
proteins, such as sperm receptors ZP1 and ZP3 and tectorial
membrane components a- and b-tectorin, and is essential for
protein polymerization7 (Figure 1b). Indeed, uromodulin is
mainly present in the urine as a high-molecular-weight
polymer (Mr 1–10 106Da) that appears at the electron
microscopy analysis as a matrix composed by fibrils, with a
width of about 100 A˚ and an average length of 25,000 A˚.
Depending on the ionic conditions, uromodulin matrices can
form a gel-like structure that is water impermeable but allows
ion movement.8
Timing and tissue specificity of expression
Uromodulin is a kidney-specific protein that is exclusively
expressed by epithelial cells lining the thick ascending limb
(TAL) of Henle’s loop.9 It is mainly located at the apical
plasma membrane,10 although localization at the basolateral
side of TAL cells has also been reported.11 A basolateral
release of uromodulin is suggested by studies on its
trafficking in transfected polarized epithelial cells and by its
presence at very low concentrations in the blood.12
The presence of uromodulin protein and transcript is
detected from embryonic day 16.5 in the developing mouse
kidney.13,14 In humans, the protein was detected from
gestational week 16 by immunohistochemistry analysis and
from week 20 in the amniotic fluid.15 Its expression steadily
increases with time and maturation of TAL tubules till after
birth. Uromodulin is the most abundant transcript in mature
TAL cells where it is produced at a very high rate.16 The half-life
of the protein is rather short (about 9 h in rabbit and 16 h in
humans)17 due to its high rate of secretion in the urine that
ranges from 20 to 100mg/day in humans under physiological
conditions.18 Uromodulin is released from the apical plasma
membrane of epithelial cells into the tubule lumen via a
conserved proteolytic cleavage.19 Cleavage is necessary for
protein polymerization, as it releases an inhibitory motif that
prevents premature protein assembly,20 similarly to what
described for ZP protein ZP3 (ref. 21) (Figure 1b). Interest-
ingly, data from our studies in transfected MDCK cells20 and
from urine peptidomes22 suggest the presence of an alternative
cleavage distal to the inhibitory motif releasing monomeric
uromodulin. Little information is currently available on the
presence of a specific protease(s) involved in uromodulin
excretion in the urine and on how this is regulated.
Evolutionary conservation
The sequence and domain composition of uromodulin is
very similar to the one of glycoprotein 2, which is the major
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Figure 1 | Structure and maturation of uromodulin. (a) The predicted structure of uromodulin contains a leader peptide (predicted to be
cleaved at residue 23), three epidermal growth factor (EGF)-like domains (EGF-II and EGF-III are calcium binding), a central domain of
unknown function (named D8C as it contains eight conserved cysteines), a zona pellucida (ZP) domain, and a glycosylphosphatidylinositol
(GPI)-anchoring site (predicted at position 614). The seven N-glycosylation sites are indicated. The high-mannose chain on residue Asn 274 is
shown in red. (b) Model of uromodulin maturation, excretion, and polymerization. Uromodulin is synthesized in thick ascending limb (TAL)
tubular epithelial cells. It is co-translationally inserted in the endoplasmic reticulum where GPI anchoring, formation of intramolecular
disulfide bonds, and N-glycosylation take place. In the Golgi, all glycan chains are modified, with the exception of the one on Asn 274 that
retains a high-mannose moiety. Uromodulin reaches the plasma membrane in a polymerization-incompetent conformation kept by the
interaction of two hydrophobic motifs (red), one within the ZP domain (internal hydrophobic patch) and one localized between the ZP
domain and the GPI-anchoring site (external hydrophobic patch). Proteolytic cleavage by a yet to be identified protease (scissors) releases
the hydrophobic interaction, generating a polymerization-competent monomer that is assembled into polymeric filaments. The orientation
of uromodulin monomers within a filament is hypothetical and deduced from structural data on ZP3 protein.94
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component of zymogen granule membranes of exocrine
pancreas, and liver-specific ZP domain-containing protein.
Glycoprotein 2 and UMOD genes lie adjacent on chromo-
some 16p12.3, suggesting that they could have evolved
through duplication divergence of a common ancestral gene.
As uromodulin (see below), glycoprotein 2 protein is able to
bind to Escherichia coli of the fimbriated type I, suggesting
that the two proteins exert similar protective functions in the
urinary and digestive systems.23
Uromodulin is present in the kidney of all mammals.
Immunoreactive protein in the layers of the skin of several
amphibians and fishes, and in the distal tubules of the kidney
of some amphibians, was reported.24 Comparative genomics
analysis reveals putative UMOD homologs in amphibian
(Xenopus tropicalis) and fish (Danio rerio) genomes, with
significant sequence similarity at the predicted protein level.
The function of these homologs and their relevance for
comparative physiology remain to be determined.
Biological function
The biological function of uromodulin is still rather elusive.
Uromodulin has been hypothesized to have a role in water/
electrolyte balance in the TAL. This hypothesis is based on its
gelification and physico-chemical properties,8 and on the
evidence that its expression is increased by a high-salt diet
and by chronic administration of the loop diuretic furose-
mide.25 More direct evidence comes from a recent work by
Renigunta et al. showing that expression of uromodulin
significantly increases the activity of ROMK2 channel
through direct interaction and positive regulation of its
delivery to the plasma membrane. Lack of uromodulin in
Umod knockout mice leads to significant upregulation of
ROMK2, which results from a reduction of the channel
amount at the plasma membrane and its increase in the
vesicular pool.26 However, the specificity of this effect
requires further investigation, as ion transporters of down-
stream segments (Na-Cl cotransporter, a-epithelial Na
channel) were also found to be significantly upregulated in
uromodulin-deficient mice.27
Studies in Umod knockout mice showed that uromodulin
has a defensive role against urinary tract infection (UTI).28,29
This function is due to its ability to bind to pathogens of the
urinary tract, for example, type 1-fimbriated E. coli,
competing with their binding to uroplakins on the
urothelium30 and is mediated by its high-mannose moiety.
Indeed, one the seven sites of glycosylation (Asn 274) retains
a high-mannose chain (Figure 1a), a feature that is conserved
throughout evolution and that likely depends on the protein
primary structure and folding.18 Uromodulin also has a role
in preventing the formation of kidney stones. Several in vitro
studies31 complemented by in vivo investigations on a rat
nephrolithiasis model32 showed that uromodulin reduces
the aggregation of calcium crystals. Moreover, lack
of uromodulin in knockout mice leads to the formation of
calcium crystals in the kidneys and progressive renal
calcification.33,34 Uromodulin exerts its protective function
acting synergistically with osteopontin, as shown in double
knockout mice.35 Although supported by in vivo evidence in
Umod knockout mice, the relevance of uromodulin as a
protective molecule against UTI and nephrolithiasis is still
unclear. Indeed, individuals with extremely reduced uromo-
dulin urinary level, as patients carrying UMOD mutations
(see below), do not show increased rates of UTIs or renal
stone formation.
Finally, uromodulin has also been suggested to have a role
in innate immunity of the kidney. Several in vitro studies
demonstrated that it can bind to immunity-related mole-
cules, such as immunoglobulin G, complement 1q, and
tumor necrosis factor-a.36–38 Uromodulin can also act as a
chemoattractant39 and as a proinflammatory molecule, able
to interact with and activate components of the immune
system, including monocytes, neutrophils,39 and myeloid
dendritic cells via toll-like receptor 4.40 Administration of
uromodulin induces tubulointerstitial nephritis in rabbits,
rats, and mice.41,42 In the mouse, this is accompanied by the
production of anti-uromodulin antibodies, which is depen-
dent on toll-like receptor 4 function.40 Taken together, these
data suggest that uromodulin may act as a danger-signaling
molecule, able to elicit an inflammatory response following
conditions that damage the nephron integrity and lead to
uromodulin release in the interstitial space. This hypothesis is
supported by the evidence of interstitial uromodulin release
associated with inflammatory cell infiltrate as well as of
increased uromodulin-specific autoantibodies in several
inflammatory disorders and infections of the urinary tract.43
However, the proinflammatory role of uromodulin remains
controversial and has been recently challenged by El-Achkar
et al.,44 who showed that mice lacking uromodulin develop
more functional and histological renal damage after ische-
mia–reperfusion injury compared with wild-type animals.
UROMODULIN-ASSOCIATED KIDNEY DISEASES
Mutations in the UMOD gene cause medullary cystic kidney
disease type 2 (MIM 603860) and familial juvenile hyperur-
icemic nephropathy (MIM 162000) that are autosomal
dominant tubulointerstitial kidney diseases. Being allelic
disorders, medullary cystic kidney disease type 2 and familial
juvenile hyperuricemic nephropathy are collectively referred
to as uromodulin-associated kidney disease (UAKD).45
UAKD is a rare disorder. About 50 mutations have been
reported so far (see below), and its prevalence is estimated to
be 1/100,000 (http://www.orphanet.org). The earliest symp-
tom in UAKD patients is often hyperuricemia that results
from reduced fractional excretion of uric acid, is present in
B80% of patients, and is frequently associated with gout.45,46
Mild urine-concentrating ability is an almost constant
finding, sometimes resulting in polyuria and polydipsia.47
Chronic renal failure generally occurs between the second
and fourth decade of life, although a significant intra- and
interfamilial variability has been observed. At the histological
analysis, UAKD is characterized by diffuse tubulointerstitial
fibrosis with moderate inflammatory cell infiltrate and
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tubular atrophy.47,48 Renal cysts (generally measuring
0.5–3 cm in diameter) are sometimes detected, mainly at
the corticomedullary junction.47,49,50 There is no specific
therapy other than correction of water and electrolyte
imbalance that may occur. Hyperuricemia can be effectively
treated with allopurinol51 or uricosuric drugs such as
benzbromarone.52 Few follow-up data are available on
transplanted patients and suggest that renal transplant can
effectively cure UAKD.53
Mutations in the UMOD gene were also reported in two
families affected by a variant of glomerulocystic kidney
disease (MIM 609886), resembling UAKD phenotype.48,54
Patients showed marked dilation of Bowman’s space in most
glomeruli that was associated with hyperuricemia, severe
impairment of urine-concentrating ability, and no evidence
of diabetes. Interestingly, homozygosity for a UMOD
mutation has been reported in three affected individuals
from a Spanish consanguineous family.55 Homozygous
individuals display a more severe phenotype in comparison
with heterozygous members of the same family in terms of
earlier onset of hyperuricemia and faster progression to end-
stage renal disease.
The analysis of uromodulin in renal biopsies and urine
samples from patients with UAKD revealed some key
findings. Immunohistochemistry and immunofluorescence
analysis showed the presence of large uromodulin intracel-
lular aggregates in the cells lining the TAL.47,48,56,57 These
inclusions colocalize with ER markers, suggesting that
mutations affect protein delivery to the plasma mem-
brane.57,58 These findings are consistent with the presence
of fibrillar or amorphous material within expanded stacks of
the ER and of hyperplastic bundles of the ER at the
ultrastructural analysis.49,57,59 Defective transport of mutant
protein was also demonstrated by a significant decrease of the
urinary excretion of UAKD patients.47,48,57,60 The reduction
was irrespective of renal function, suggesting a possible
dominant-negative effect on the trafficking of wild-type
protein.47,60
Similar clinical findings, that is, tubulointerstitial
nephritis and hyperuricemia, can be found associated
with mutations in the gene encoding the transcription
factor hepatocyte nuclear factor-1b (TCF2; MIM 137920)61
and in the REN gene encoding renin (MIM 613093).62
Moreover, two additional loci have been mapped on
chromosome 1q21 (medullary cystic kidney disease
type 1)63 and p22.1–p21 (familial juvenile hyperuricemic
nephropathy 3).64
In vitro studies
To date, 51 UMODmutations have been published (Figure 2).
All but three (in-frame deletions) are missense changes that
affect in B50% (28/51) of the cases one of the conserved
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Figure 2 |Uromodulin genetic variants associated with chronic diseases of the kidney. Upper panel: all published uromodulin
mutations in uromodulin-associated kidney disease patients are shown relative to their localization and effect in the protein sequence. A
total of 51 mutations have been reported to date: 29 (57%) affect or introduce cysteine residues directly altering the disulfide bond pattern;
19 (37%) are missense changes affecting residues other than cysteine; and 3 (6%) are in-frame deletions. Middle panel: exon/intron structure
of the human UMOD gene. Coding parts are shown in blue. Most of UMOD mutations are clustered in exons 3 and 4. Lower panel: the
position of top single-nucleotide polymorphisms that were identified in different genome-wide association studies is shown (red). These
variants are within the same linkage disequilibrium (LD) block spanning UMOD promoter to exon 7, as shown by the LD plot (r2 values,
adapted from Haploview 4.2 output, data from HapMap CEU, release no. 28). chr, chromosome; UMOD, uromodulin; ZP, zona pellucida.
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cysteine residues. UMOD mutations are clustered (94%) in
exons 3 and 4 encoding for the N-terminal half of the
protein; only three mutations have been reported so far in
exons 5 (C347G) and 7 (A461E, G488R) and affect residues
within the ZP domain.65–67
The majority of reported UMOD mutations are predicted
to cause protein misfolding, either by directly affecting the
disulfide bond pattern or by destabilizing the structure of
EGF-like domains. Consistent with an effect of mutations on
protein folding, we demonstrated in different cellular models
that mutant uromodulin isoforms are defective in trafficking
to the plasma membrane and are retained in the ER.48,68 The
results of our in vitro studies on UMOD mutations were
confirmed by other reports on different mutation panels and
different cell lines,12,57,66 clearly showing a common effect for
all UMOD mutations. Overall, these data indicate ER
retention of mutant uromodulin as a key step in the
pathogenesis of UAKD and point at these diseases as an
additional member of the known ER storage diseases.59
Interestingly, in vitro studies suggest the presence of two
classes of UMOD mutations, according to the extent of
mutant protein retention in the ER. At the moment, no clear
genotype–phenotype could be established because of the
small number of affected families and/or incomplete or
heterogeneous available clinical data.
Although the analyses of in vitro models identified a
common effect of all UMOD mutations, they did not allow
the identification of potential pathogenetic events down-
stream of mutant uromodulin ER retention. Mutant
uromodulin expression in cellular models was reported to
lead to cell apoptosis, which could be rescued by treatment
with colchicine and sodium 4-phenylbutyrate.69 However,
evidence for a proteotoxic effect of mutant uromodulin
expression has not been observed when using different
kidney cell lines under basal or stress conditions12 (our
unpublished results). As the cellular models so far reported
were ineffective in reproducing key cellular hallmarks of the
disease, that is, mutant uromodulin aggregation, ER
membrane expansion, and dilation, and were developed in
cell lines not expressing endogenous uromodulin, it cannot
be excluded that a fully differentiated TAL cell is needed to
properly assess in vitro the effect of mutant protein
expression.
In vivo models
Two Umod knockout mouse models have been reported and
extensively characterized. As previously mentioned, these
animals are more susceptible to UTIs and more prone to
renal stone formation and nephrocalcinosis. However,
animals lacking uromodulin show few, if any, signs of UAKD,
consistent with a gain-of-function effect of UMOD muta-
tions. Indeed, no interstitial fibrosis, inflammatory infiltrate,
and renal cysts were observed up to 3 years of age.70 Umod
knockout mice show mild urinary concentrating defect after
water deprivation test, which could be due to a defect in the
TAL reabsorptive capacity.27 Recent data showing reduced
amount of ROMK2 channel at the plasma membrane in these
animals support this hypothesis.26
Noteworthy, no renal phenotype was described in a
transgenic mouse model expressing C148W human mutant
uromodulin, likely, because of low expression of the
transgene.71 A mouse expressing uromodulin variant
A227T was obtained by ethylnitrosourea mutagenesis.
The UmodA227T mice show some features of UAKD, such as
the presence of uromodulin aggregates in TAL cells, urine
concentration ability defect, and reduced fractional excretion
of uric acid. However, they lack inflammation and fibrosis
and have additional metabolic alterations.72
We recently generated and characterized an in vivo model
of UAKD, that is a transgenic mouse expressing mutant
uromodulin (TgUmodC147W).58 The mutation introduced in
the murine protein (C147W) corresponds to the human
mutation C148W that we previously identified in UAKD
patients and extensively characterized in vitro.48 The
phenotype in TgUmodC147W mice was compared with expres-
sion-matched transgenic mice for wild-type protein
(TgUmodwt). TgUmodC147W mice specifically show progressive
signs of renal damage, that is, tubulointerstitial fibrosis with
inflammatory cell infiltration and tubule dilation. Interest-
ingly, necrotic cells but no apoptosis were detected in distal
tubules. Similarly to UAKD patients, TgUmodC147Wmice show
urinary concentrating defect of renal origin that is present in
young animals and precedes renal failure. ER retention of
mutant uromodulin precedes all other features starting at 1
week of age (our unpublished results) and progressing to the
formation of massive intracellular aggregates and hyperplasia
of ER membranes in 24-week-old kidneys. TgUmodC147W mice
hence recapitulate most of the disease features, with the
exception of hyperuricemia, likely because mice express
urate oxidase, an enzyme that catalyses urate to allantoin
conversion and that is absent in primates. We believe that the
different phenotype in UmodA227T and TgUmodC147W mouse
models could be ascribed to the different genetic back-
grounds in the two models (C3HeB/FeJ versus FVB/N), to
the different expression level of total uromodulin, or to the
fact that the A227T variant was not associated with UAKD
in patients.
On the bases of current knowledge, we envisage a model of
UAKD pathogenesis in which the key primary event is ER
accumulation of mutant uromodulin in the TAL cells that
could have both a gain-of-function and a loss-of-function
effect (Figure 3a). On the one hand, it leads to TAL
functional and structural injury, as suggested by findings in
TgUmodC147Wmice. On the other hand, it reduces the amount
of uromodulin entering the secretory pathway and reaching
the apical membrane, also affecting the trafficking of the
wild-type protein. This could affect the efficient delivery of
ion transporters in the TAL segment, as suggested by reduced
amount of ROMK at the apical plasma membrane in the
Umod knockout mouse.26 The loss of functional TAL
segment could explain the urinary concentrating defect in
UAKD and lead to hyperuricemia. The latter could be due to
342 Kidney International (2011) 80, 338–347
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a compensatory sodium uptake in the proximal tubule,59 by a
mechanism similar to the one causing hyperuricemia during
chronic loop diuretic administration.73 The inflammatory
process in the kidney of TgUmodC147Wmice could be triggered
by ER stress pathways activated in TAL cells and/or by TAL
cell necrosis, eventually resulting in progressive interstitial
fibrosis and tissue scarring, a final common pathway for
many acute and chronic kidney injuries. Although we did not
detect significant evidence of interstitial uromodulin, we
cannot exclude the possibility that inflammation could be
enhanced by basolateral release of mutant uromodulin. An
increase of uromodulin in the serum, possibly as a
consequence of its interstitial release, was indeed reported
in some UAKD patients12 and could lead to the induction of
proinflammatory cytokines.74 Renal cysts in UAKD could be
a consequence of progressive TAL cellular damage and
secondary proliferation. Recent findings showing the pre-
sence of uromodulin in primary cilia and a significant
reduction of ciliary uromodulin in UAKD patients suggest
the possibility that cysts could be related to cilia dysfunc-
tion.75 However, this seems unlikely taking into account the
lack of renal cysts in Umod knockout mice and recent
evidence that strong Umod gene downregulation is not
sufficient to induce cystogenesis following hepatocyte nuclear
factor-1b inactivation in mouse.76
Further studies will be needed to address this and other
open questions that would have relevance for potential
therapeutic strategies, such as the identification of the
stress pathways that are activated by mutant uromodulin
ER retention, the molecular basis of inflammation and
fibrosis, and the contribution of each factor in disease
progression.
UROMODULIN INVOLVEMENT IN OTHER PATHOLOGICAL
CONDITIONS OF THE KIDNEY
Several studies reported association of uromodulin abnor-
malities with pathological conditions of the kidney. This
includes accumulation of uromodulin in cast nephropathy
and presence of protein deposits in the renal interstitium in
reflux nephropathy, rejecting renal allografts and interstitial
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Figure 3 |Uromodulin and chronic diseases of the kidney. (a) In uromodulin-associated kidney disease, mutations in UMOD cause
endoplasmic reticulum (ER) retention and aggregation of mutant protein. This leads to thick ascending limb (TAL) dysfunction and urinary
concentrating defect and to a dramatic decrease of uromodulin urinary levels, suggesting a dominant-negative effect on the transport of
wild-type uromodulin to the plasma membrane. This effect could also affect the delivery of other proteins, for example, ion transporters, on
the plasma membrane, contributing to TAL dysfunction. Through a still unknown mechanism, intracellular retention eventually results in
TAL cell damage and necrosis, leading to fibrosis and inflammatory cell infiltrate. Inflammation could be enhanced by basolateral release of
uromodulin. (b) Genome-wide association studies identified UMOD variants that are associated with estimated glomerular filtration rate and
increased risk of chronic kidney disease (CKD), hypertension, and cardiovascular disease. These variants are associated with increased
urinary uromodulin levels that could be due to increased uromodulin expression, decreased membrane-anchoring efficiency, faster protein
sorting to the apical membrane, or increased proteolytic release. The causal relationship among UMOD variants, increased urinary
uromodulin, and development of CKD, hypertension, or cardiovascular disease is presently unknown.
GPI, glycosylphosphatidylinositol.
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diseases.77–80 These deposits are sometimes associated
with inflammatory infiltrate. Additionally, uromodulin
urinary excretion is positively correlated with the estimated
glomerular filtration rate (eGFR) and is reduced in several
conditions affecting kidney function and/or integrity,
including glomerulonephritis, diabetes nephropathy, lupus
nephritis, tubulointerstitial nephropathy, and polycystic
kidney disease.81 The use of urinary uromodulin as a
diagnostic marker of renal disease has been recently
questioned in an analysis of uromodulin urinary levels in
77 patients with chronic kidney disease (CKD), showing that
22% of the analyzed patients have normal urinary levels of
uromodulin.74 Qualitative changes in uromodulin processing
have also been reported. The presence of shorter, abnormally
processed urinary uromodulin fragments was observed in
Fabry disease patients.82 Interestingly, the urinary excretion
of shorter uromodulin fragments was significantly decreased
following enzyme replacement therapy.
UROMODULIN IN GENOME-WIDE ASSOCIATION STUDIES
Genome-wide association studies (GWAS) have successfully
identified genomic loci containing susceptibility variants
associated with the risk of complex traits and markers of
renal function (for review, see ref. 83). In particular, common
variants in the UMOD gene have been associated with the
risk of CKD, eGFR, and other complex traits, such as kidney
stones and hypertension (Table 1, Figure 2).
The first GWAS on CKD, conducted in B20,000
participants of European ancestry from unselected,
population-based cohorts from the CHARGE Consortium,
identified a top single-nucleotide polymorphism
(rs12917707) located 3.4 kb upstream of UMOD associated
with the risk of CKD. The minor T allele of rs12917707 was
associated with a 20% reduction in the risk of CKD, and the
association was independent of major kidney disease risk
factors, including older age, male gender, and presence of
hypertension or diabetes. Further prospective data from the
ARIC Study (n¼ 952 cases) showed that the T allele of
rs12917707 was associated with a lower relative hazard
of incident CKD over B15 years of follow-up (hazard
ratio¼ 0.81, 95% confidence interval¼ 0.72–0.92).84 The
strong association of rs12917707 with CKD was supported
by a subsequent analysis performed in the CKDGen
Consortium.85 It is important to note that the rs12917707
variant of UMOD was also associated with two indices of
renal function, eGFRcrea and eGFRcys, based on serum
creatinine and serum cystatin C, respectively.84,85 The
rs12917707 variant of UMOD was associated with both
higher eGFRcys and eGFRcrea, and lower risk of developing
CKD, consistent with a protective effect.84,85 As expected,
the variants described above explain a small percentage
(typically, o1%) of the variance in eGFRcrea. Of note,
there was no significant association of rs12917707 with
hyperuricemia and gout.84
Table 1 |UMOD variants and traits identified by GWAS
Top SNP Positiona (bp) Trait Consortiumb Discovery cohort (n) Replication (n) Reference
rs12917707 3403 CKDc CHARGE 19,877 21,466 Kottgen et al.84
rs12917707 3403 CKDc CKDGen 62,237 NA Kottgen et al.85
rs12917707 3403 eGFRcrea CHARGE 18,127 21,466 Kottgen et al.84
rs12917707 3403 eGFRcys CHARGE 12,266 NA Kottgen et al.84
rs12917707 3403 eGFRcrea CKDGen 67,093 NA Kottgen et al.85
rs12917707 3403 eGFRcys CKDGen 20,957 NA Kottgen et al.85
rs4293393 300 sCreat EUROSPANd 4006 NA Pattaro et al.87
rs12917707 3403 sCreat Nine studiese 23,090 16,626 Chambers et al.88
rs4293393 300 CKD Iceland 2903 versus 35,818f 300 versus 2964f Gudbjartsson et al.86
rs4293393 300 sCreat Iceland 22,256 2379 Gudbjartsson et al.86
rs4293393 300 sUrate Iceland 6583 NA Gudbjartsson et al.86
rs4293393 300 sUrea Iceland 4084 NA Gudbjartsson et al.86
rs4293393 300 Kidney stones Iceland 1689 versus 37,076f 1972 versus 6125f,g Gudbjartsson et al.86
rs13333226 1867 Hypertensionh Global BPgen 1621 versus 1699f 19845 versus 1654f Padmanabhan et al.90
Abbreviations: CKD, chronic kidney disease; eGFRcrea, estimated glomerular filtration rate based on serum creatinine; eGFRcys, estimated glomerular filtration rate based on
serum cystatin C; GWAS, genome-wide association study; LD, linkage disequilibrium; NA, not available; sCreat, serum creatinine; SNP, single-nucleotide polymorphism; sUrate,
serum urate; UMOD, uromodulin.
aPosition relative to UMOD transcription start site (UCSC Genome Browser, GRCh37).
bAll cohorts are from European descent.
cCKD definition: eGFRo60ml/min per 1.73m2 using the Modification of Diet in Renal Disease study equation.
dEUROSPAN is a combination of five European genetic isolates.
eEuropean participants from the following studies: LOLIPOP, CoLaus, SardiNIA, TwinsUK, BRIGHT, Fenland, NFBC1966, NESDA, and InChianti.
fCases versus controls.
gCombined replication on Icelandic and Dutch subjects.
hHypertension defined as at least two consecutive blood pressure measurements of X160mmHg systolic andX100mmHg diastolic pressure, with diagnosis made before
age 63 years.
The frequency of the minor allele for rs12917707, rs13333226, and rs4293393 isB0.18. All the indicated SNPs are in complete LD (D0=1, r2=1; HapMap CEU, release no. 28).
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An independent replication of the findings of Ko¨ttgen
et al.84 was provided by Gudbjartsson et al.,86 who showed
that the single-nucleotide polymorphism rs4293393, located
300 bp upstream of UMOD, is associated with increased risk
of CKD and elevated serum creatinine in a large Icelandic
population. The rs4293393 variant was also associated with
increased serum levels of uric acid and increased risk of gout,
and a lower risk of formation of calcium-containing kidney
stones in the Icelandic population. The association of the
rs4293393 and rs12917707 variants with serum creatinine
levels was confirmed in a meta-analysis of five European
isolates (EUROSPAN)87 and in the large European cohort
reported by Chambers et al.88 Of note, the rs4293393 variant
is in perfect linkage disequilibrium in the HapMap CEU89
with the rs12917707 variant (D0 ¼ 1; r2¼ 1; Figure 2).
Recently, the Global BPGen Consortium used an extreme
case–control design to identify a locus in the 50 region of
UMOD (rs13333226) associated with hypertension.90 The
minor G allele of rs13333226 was associated with a lower risk
of hypertension (odds ratio¼ 0.6; 95% confidence inter-
val¼ 0.5–0.73), with each copy of the G allele being
associated with 0.49mmHg lower systolic blood pressure
and 0.30mmHg lower diastolic blood pressure. The minor
allele of rs13333226 was also associated with eGFR, but
adjustment for this variable in a subset of 13,466 individuals
confirmed the association of rs13333226 with lower risk for
hypertension. The rs13333226 variant of UMOD was also
associated with long-term cardiovascular outcomes among
the 26,654 subjects from the Swedish population-based MDC
Study: each copy of the G allele associated with a 7.7%
reduction in risk of cardiovascular disease after adjusting for
age, sex, body mass index, and smoking status followed up
for 12 years. The rs13333226 variant is in complete linkage
disequilibrium with rs4293393 and rs12917707 variants
(D0 ¼ 1, r2¼ 1, HapMap CEU; Figure 2).
Typically, GWAS yield loci that are statistically associated
with a quantitative trait or a disease state. In an effort to
evaluate the functional link among variants in UMOD, the
level of uromodulin in the urine, and the risk of developing
CKD, Ko¨ttgen et al.91 performed a nested case–control study
(n¼ 200) of incident CKD (followed up for 9.9 years) within
the Framingham Heart Study. They showed that baseline
urinary uromodulin levels were 51% higher in CKD than
controls and that the protective C allele of rs4293393 was
associated with lower urinary uromodulin levels and higher
eGFR in a dose-dependent manner.91 The perfectly correlated
minor G allele of rs13333226 (which is protective against
hypertension) was associated with lower urinary excretion of
uromodulin in a subset of participants of the population-
based HERCULES Study (n¼ 110) and hypertensive indivi-
duals from the BRIGHT Study (n¼ 256), with a potential
relation with lower fractional excretion of sodium and lower
endogenous lithium clearance.90 The minor T allele of
rs12917707, which is protective for CKD, was also shown
to be associated with lower urinary uromodulin among
coronary artery disease patients (n¼ 120) from the Heart and
Soul Study.92 However, in these patients, the urinary levels of
uromodulin were not associated with CKD, suggesting that
different mechanisms could be responsible for kidney
function decline in patients with and without coronary
artery disease. With the limitation of small sample size and
complexity of the factors (age, renal function, diet, drugs,
etc.) influencing the excretion of uromodulin, these studies
(i) point to the potential of uromodulin as a biomarker for
CKD and (ii) suggest that higher urinary excretion of
uromodulin may be deleterious and precede the development
of CKD and/or hypertension (Figure 3b).
Future studies should confirm the potential association
between UMOD variants and blood pressure (as a continuous
trait) and investigate the causality of the variants described
above, which are all in strong linkage disequilibrium in the 50
region of UMOD, or determine causal variants by resequen-
cing. They should also characterize the factors influencing the
urinary excretion of uromodulin in large cohorts, as well as
the function, regulation, and functional interactions of
uromodulin in the epithelial cells lining the TAL in the
human kidney.93 The transgenic and knockout mouse models
described above will undoubtedly be useful to analyze the
role of uromodulin and distinct between primary effects or
functional adaptations caused by its deletion or overexpres-
sion in the kidney.
CONCLUSIONS AND PERSPECTIVES
The last ten years have witnessed a rediscovery of uromodu-
lin, thanks to key findings from in vivo investigations, genetic
analysis in Mendelian disorders, characterization of different
mouse models, and GWAS. This has led to a scientific
renaissance of the field that will boost future studies on the
precise role of uromodulin in the TAL and its potential link
with ion transport and innate immunity of the kidney, the
molecular mechanisms that regulate its expression and
secretion, the significance of its basolateral and urinary
release, and its use as a biomarker. Moreover, studies on
UAKD will help understanding the pathophysiology of the
TAL segment and will take advantage of preclinical models to
identify potential therapeutic strategies. Finally, the associa-
tion of uromodulin with CKD and hypertension will need
further investigation to clarify the biological effect of the
identified risk variants and to evaluate linked variants that
may have a causal role.
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